Literature DB >> 19241117

Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells.

Minenori Eguchi-Ishimae1,2, Mariko Eguchi1,2, Kazuma Ohyashiki3, Tetsuya Yamagata1, Kinuko Mitani4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19241117     DOI： 10.1007/s12185-009-0267-8

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  13 in total

1.  Quantitative comparison of the expression of EVI1 and its presumptive antagonist, MDS1/EVI1, in patients with myeloid leukemia.

Authors:  Ursula Vinatzer; Christine Mannhalter; Margit Mitterbauer; Helga Gruener; Hildegard Greinix; Helmut H Schmidt; Christa Fonatsch; Rotraud Wieser
Journal:  Genes Chromosomes Cancer       Date:  2003-01       Impact factor: 5.006

Review 2.  NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.

Authors:  Takuro Nakamura
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

3.  NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells.

Authors:  Akiko Takeda; Charles Goolsby; Nabeel R Yaseen
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

4.  The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia.

Authors:  Lars Palmqvist; Bob Argiropoulos; Nicolas Pineault; Carolina Abramovich; Laura M Sly; Gerald Krystal; Adrian Wan; R Keith Humphries
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

5.  Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.

Authors:  Dragana Jankovic; Paolo Gorello; Ting Liu; Sabire Ehret; Roberta La Starza; Cecile Desjobert; Florent Baty; Martin Brutsche; Padma-Sheila Jayaraman; Alessandra Santoro; Christina Mecucci; Juerg Schwaller
Journal:  Blood       Date:  2008-04-03       Impact factor: 22.113

Review 6.  Leukemogenesis of the EVI1/MEL1 gene family.

Authors:  Kazuhiro Morishita
Journal:  Int J Hematol       Date:  2007-05       Impact factor: 2.490

7.  Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model.

Authors:  Masayuki Iwasaki; Takeshi Kuwata; Yukari Yamazaki; Nancy A Jenkins; Neal G Copeland; Motomi Osato; Yoshiaki Ito; Evert Kroon; Guy Sauvageau; Takuro Nakamura
Journal:  Blood       Date:  2004-09-28       Impact factor: 22.113

8.  Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1.

Authors:  Katherine R Calvo; David B Sykes; Martina P Pasillas; Mark P Kamps
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

9.  Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia.

Authors:  T Nakamura; D A Largaespada; M P Lee; L A Johnson; K Ohyashiki; K Toyama; S J Chen; C L Willman; I M Chen; A P Feinberg; N A Jenkins; N G Copeland; J D Shaughnessy
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

10.  High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

Authors:  Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Claudia Erpelinck; Wim L J van Putten; Peter J M Valk; Sonja van der Poel-van de Luytgaarde; Ronald Hack; Rosalyn Slater; Elisabeth M E Smit; H Berna Beverloo; Gregor Verhoef; Leo F Verdonck; Gert J Ossenkoppele; Pieter Sonneveld; Georgine E de Greef; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113
View more
  3 in total

1.  The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms.

Authors:  Jason R Schwartz; Jing Ma; Jennifer Kamens; Tamara Westover; Michael P Walsh; Samuel W Brady; J Robert Michael; Xiaolong Chen; Lindsey Montefiori; Guangchun Song; Gang Wu; Huiyun Wu; Cristyn Branstetter; Ryan Hiltenbrand; Michael F Walsh; Kim E Nichols; Jamie L Maciaszek; Yanling Liu; Priyadarshini Kumar; John Easton; Scott Newman; Jeffrey E Rubnitz; Charles G Mullighan; Stanley Pounds; Jinghui Zhang; Tanja Gruber; Xiaotu Ma; Jeffery M Klco
Journal:  Nat Commun       Date:  2021-02-12       Impact factor: 14.919

2.  Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.

Authors:  T Sato; S Goyama; K Kataoka; R Nasu; T Tsuruta-Kishino; Y Kagoya; A Nukina; K Kumagai; N Kubota; M Nakagawa; S Arai; A Yoshimi; H Honda; T Kadowaki; M Kurokawa
Journal:  Oncogene       Date:  2014-04-21       Impact factor: 9.867

Review 3.  Rare Cytogenetic Abnormalities and Alteration of microRNAs in Acute Myeloid Leukemia and Response to Therapy.

Authors:  Mohammad Shahjahani; Elahe Khodadi; Mohammad Seghatoleslami; Javad Mohammadi Asl; Neda Golchin; Zeynab Deris Zaieri; Najmaldin Saki
Journal:  Oncol Rev       Date:  2015-03-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.